CAR-T for Multiple Myeloma: How to Choose Between Therapies?

(MedPage Today) -- CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or refractory multiple myeloma.
In 2021, the FDA approved idecabtagene vicleucel (ide-cel, Abecma) for patients...